|1.||Pines, Mark: 33 articles (01/2016 - 05/2002)|
|2.||Nagler, Arnon: 19 articles (01/2015 - 05/2002)|
|3.||Halevy, Orna: 11 articles (01/2016 - 06/2006)|
|4.||Genin, Olga: 9 articles (09/2015 - 02/2007)|
|5.||Nagler, A: 7 articles (04/2007 - 11/2000)|
|6.||Pines, M: 6 articles (04/2007 - 11/2000)|
|7.||Genina, Olga: 5 articles (06/2006 - 09/2002)|
|8.||Paizi, Melia: 4 articles (06/2008 - 09/2002)|
|9.||Spira, Gadi: 4 articles (06/2008 - 09/2002)|
|10.||Genina, O: 4 articles (04/2007 - 11/2000)|
08/01/2010 - "We evaluated the efficacy of halofuginone in reducing fibrosis in the dy(2J)/dy(2J) mouse model of congenital MD. "
11/01/2008 - "Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone."
04/01/2014 - "More recently studies have also shown that halofuginone acts as an agent capable of reducing fibrosis, an indication with clinical relevance for several disease states. "
06/01/2006 - "In this study, we evaluated the effect of halofuginone on PRL-1 expression, its cellular localization in vitro and during liver regeneration, and fibrosis progression in vivo. "
07/01/2003 - "The results of the human studies provide basis for using halofuginone treatment for dermal fibrosis. "
09/01/1986 - "Halofuginone was also highly effective in preventing buildup of infection in pens contaminated by indirect means (movement by caretakers through the pens, etc.). "
08/01/2012 - "The histological slide examination noted that halofuginone was effective when provided 0-2 days post inoculation but only partially effective when applied 3-7 days post infection. "
10/01/2009 - "For prophylactic treatment, halofuginone had an effect on infection and diarrhoeal prevalence on study days 4 and 7, but the control group had significantly lower infection prevalence than the halofuginone treated group on study day 21. "
09/01/1985 - "The effect of HPS (halofuginonepolystyrene sulfonate), a derivative of halofuginone with lower toxicity, on natural leucocytozoon and coccidial infection in broiler chickens was evaluated in a floor pen trial. "
11/01/1979 - "Halofuginone at 3 ppm in the ration was tested against turkey coccidial infections caused by four species, in a series of eight battery trials of 16 days duration. "
09/01/2003 - "In vivo magnetic resonance imaging analysis of tumors in halofuginone-treated animals showed a significant reduction of vascular functionality. "
01/01/2015 - "Halofuginone (HF) is a low-molecular-weight alkaloid that has been demonstrated to interfere with Metalloproteinase-2 (MMP-2) and Tumor Growth Factor-β (TGF-β) function and, to present antiangiogenic, antiproliferative and proapoptotic properties in several solid tumor models. "
06/01/2012 - "Halofuginone (HF), a synthetic derivative of quinazolinone alkaloid, has recently been shown to have anti-cancer activity in various preclinical settings. "
10/01/2010 - "Preincubation of the PSCs with halofuginone elicited Cygb/STAP level reduction and tumor growth inhibition. "
08/01/2006 - "In addition, halofuginone has been shown to inhibit angiogenesis and tumor progression. "
12/01/2007 - "Halofuginone treatment was effective in preventing and in reducing the death rate of cryptosporidiosis in these flocks."
12/01/2007 - "Halofuginone was effective in the treatment of diarrhoea caused by cryptosporidiosis (P < 0.01). "
12/01/2007 - "The first trial was designed to assess the efficacy of halofuginone in treating lamb diarrhoea caused by cryptosporidiosis, and in preventing the disease, using two schemes; halofuginone given for seven and for three consecutive days respectively. "
10/01/2009 - "To develop more precise estimates of the effects of halofuginone on calf cryptosporidiosis, meta-analyses were performed, including studies on prophylactic and therapeutic treatment. "
12/01/2007 - "The third trial was designed to examine the ability of halofuginone to reduce the death rate in flocks with cryptosporidiosis. "
02/01/1986 - "Weight gains were significantly improved by 1.5 or 3 ppm of halofuginone, and intestinal lesion scores and fecal droppings scores were greatly reduced. "
09/01/1986 - "Weight gains and feed conversion were best in poults receiving halofuginone, whether directly or indirectly exposed. "
02/01/1986 - "Treatment with 6 ppm of halofuginone gave good protection but appeared to depress weight gains slightly. "
09/01/1985 - "HPS at 40 ppm which corresponds to the recommended level of halofuginone (3 ppm) and at 60 ppm had no adverse effect on the weight gain in experimental birds."
11/01/1979 - "Halofunginone, at 3 ppm in the ration, was highly effective (P less than .01) against all six isolates as measured by weight gain at D+6 or +7and D+12 or +14 postinoculation; feed efficiency at D-2 to D+12 or +14; morbidity; mortality; dropping score; lesion score (D+6 or +7); and oocyst production during 4 or 5 days postinoculation (D = day of inoculation). "
|4.||Collagen Type I (Type I Collagen)
|5.||Transforming Growth Factor beta (TGF-beta)
|9.||Transforming Growth Factors (Transforming Growth Factor)
|1.||Heterologous Transplantation (Xenotransplantation)
|2.||Drug Therapy (Chemotherapy)